These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25139343)

  • 21. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.
    Cook AL; Kishnani PS; Carboni MP; Kanter RJ; Chen YT; Ansong AK; Kravitz RM; Rice H; Li JS
    Genet Med; 2006 May; 8(5):313-7. PubMed ID: 16702882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients.
    Bernstein DL; Bialer MG; Mehta L; Desnick RJ
    Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
    Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
    Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infantile-onset Pompe disease: a diagnosis not to miss.
    Dixon CA; Anderson JB; Ruddy RM; Cripe LH
    Pediatr Emerg Care; 2010 Apr; 26(4):293-5. PubMed ID: 20386415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzyme replacement therapy for infantile-onset Pompe disease.
    Chen M; Zhang L; Quan S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy.
    Berrier KL; Kazi ZB; Prater SN; Bali DS; Goldstein J; Stefanescu MC; Rehder CW; Botha EG; Ellaway C; Bhattacharya K; Tylki-Szymanska A; Karabul N; Rosenberg AS; Kishnani PS
    Genet Med; 2015 Nov; 17(11):912-8. PubMed ID: 25741864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ptosis in Pompe disease: common genetic background in infantile and adult series.
    Ravaglia S; Bini P; Garaghani KS; Danesino C
    J Neuroophthalmol; 2010 Dec; 30(4):389-90. PubMed ID: 21107130
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiopulmonary exercise test to quantify enzyme replacement response in pediatric Pompe disease.
    Bar-Yoseph R; Mandel H; Mainzer G; Gur M; Tal G; Shalloufeh G; Bentur L
    Pediatr Pulmonol; 2018 Mar; 53(3):366-373. PubMed ID: 29356433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.
    Kanters TA; van der Ploeg AT; Kruijshaar ME; Rizopoulos D; Redekop WK; Rutten-van MÓ§lken MPMH; Hakkaart-van Roijen L
    Orphanet J Rare Dis; 2017 Dec; 12(1):179. PubMed ID: 29237491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up.
    Spiridigliozzi GA; Heller JH; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):22-9. PubMed ID: 22253038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease.
    Gupta P; Shayota BJ; Desai AK; Kiblawi F; Myridakis D; Messina J; Tah P; Tambini-King L; Kishnani PS
    Front Immunol; 2020; 11():1929. PubMed ID: 33013846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electrocardiographic response to enzyme replacement therapy for Pompe disease.
    Ansong AK; Li JS; Nozik-Grayck E; Ing R; Kravitz RM; Idriss SF; Kanter RJ; Rice H; Chen YT; Kishnani PS
    Genet Med; 2006 May; 8(5):297-301. PubMed ID: 16702879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distal muscle weakness is a common and early feature in long-term enzyme-treated classic infantile Pompe patients.
    van den Dorpel JJA; Poelman E; Harlaar L; van Kooten HA; van der Giessen LJ; van Doorn PA; van der Ploeg AT; van den Hout JMP; van der Beek NAME
    Orphanet J Rare Dis; 2020 Sep; 15(1):247. PubMed ID: 32928284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
    Desai AK; Baloh CH; Sleasman JW; Rosenberg AS; Kishnani PS
    Front Immunol; 2020; 11():1727. PubMed ID: 32849613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report.
    Rovelli V; Zuvadelli J; Piotto M; Scopari A; Dionigi AR; Ercoli V; Paci S; Cefalo G; Salvatici E; Banderali G
    Ital J Pediatr; 2022 Mar; 48(1):48. PubMed ID: 35346323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early cognitive development in children with infantile Pompe disease.
    Spiridigliozzi GA; Heller JH; Case LE; Jones HN; Kishnani PS
    Mol Genet Metab; 2012 Mar; 105(3):428-32. PubMed ID: 22217428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early higher dosage of alglucosidase alpha in classic Pompe disease.
    Spada M; Pagliardini V; Ricci F; Biamino E; Mongini T; Porta F
    J Pediatr Endocrinol Metab; 2018 Dec; 31(12):1343-1347. PubMed ID: 30433875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fractures in children with Pompe disease: a potential long-term complication.
    Case LE; Hanna R; Frush DP; Krishnamurthy V; DeArmey S; Mackey J; Boney A; Morgan C; Corzo D; Bouchard S; Weber TJ; Chen YT; Kishnani PS
    Pediatr Radiol; 2007 May; 37(5):437-45. PubMed ID: 17342521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.